These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7222106)

  • 41. Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.
    Nesfield SR; Clarke CJ; Hoivik DJ; Miller RT; Allen JS; Selinger K; Santostefano MJ
    Int J Toxicol; 2005; 24(5):301-11. PubMed ID: 16257850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation of the potential for binding of di(2-ethylhexyl) phthalate (DEHP) to rat liver DNA in vivo.
    Lutz WK
    Environ Health Perspect; 1986 Mar; 65():267-9. PubMed ID: 3709452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Change of the sex-dependent response to clofibrate in F344 rat liver during postnatal development.
    Yamoto T; Ohashi Y; Furukawa T; Teranishi M; Manabe S; Makita T
    Toxicol Lett; 1996 May; 85(2):77-83. PubMed ID: 8650696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.
    Emudianughe TS; Caldwell J; Sinclair KA; Smith RL
    Drug Metab Dispos; 1983; 11(2):97-102. PubMed ID: 6133730
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacology of fenofibrate (author's transl)].
    Kritchevsky D
    Nouv Presse Med; 1980 Dec; 9(49):3769-73. PubMed ID: 7208345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The biochemical pharmacology of fenofibrate.
    Caldwell J
    Cardiology; 1989; 76 Suppl 1():33-41; discussion 41-4. PubMed ID: 2713875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of di-isononyl phthalate, di-2-ethylhexyl phthalate, and clofibrate in cynomolgus monkeys.
    Pugh G; Isenberg JS; Kamendulis LM; Ackley DC; Clare LJ; Brown R; Lington AW; Smith JH; Klaunig JE
    Toxicol Sci; 2000 Jul; 56(1):181-8. PubMed ID: 10869467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of the hepatocarcinogenic peroxisome-proliferating hypolipidemic agents clofibrate and nafenopin on the rat liver cell membrane enzymes gamma-glutamyltranspeptidase and alkaline phosphatase and on the early stages of liver carcinogenesis.
    Numoto S; Furukawa K; Furuya K; Williams GM
    Carcinogenesis; 1984 Dec; 5(12):1603-11. PubMed ID: 6149819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague-Dawley rats treated with tumorigenic doses of clofibrate.
    Tanaka K; Smith PF; Stromberg PC; Eydelloth RS; Herold EG; Grossman SJ; Frank JD; Hertzog PR; Soper KA; Keenan KP
    Toxicol Appl Pharmacol; 1992 Sep; 116(1):71-7. PubMed ID: 1529455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Repeated dose liver micronucleus assay using clofibrate in young adult rats.
    Takayanagi T; Takashima R; Wako Y; Kawasako K; Tanaka Y; Hori H; Fujii W
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Mar; 780-781():117-22. PubMed ID: 25892631
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A metabonomics study of the hepatotoxicants galactosamine, methylene dianiline and clofibrate in rats.
    Ishihara K; Katsutani N; Aoki T
    Basic Clin Pharmacol Toxicol; 2006 Sep; 99(3):251-60. PubMed ID: 16930299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatotoxicity due to clofibrate is oxygen-dependent in the perfused rat liver.
    Keller BJ; Yamanaka H; Liang DC; Thurman RG
    Toxicol Appl Pharmacol; 1990 Jun; 104(2):259-66. PubMed ID: 2363177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of hypolipidaemic drugs on hepatomegaly and micro-bodies in the rat. A new approach to the nature of hepatic peroxisomal proliferation.
    Sim AK; Spencer A; Metz G; Rushton B
    Arzneimittelforschung; 1981; 31(7):1119-26. PubMed ID: 7196761
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of hypolipidemic drugs, nafenopin and clofibrate, on the concentration of ligandin and Z protein in rat liver.
    Fleischner G; Meijer DK; Levine WG; Gatmaitan Z; Gluck R; Arias IM
    Biochem Biophys Res Commun; 1975 Dec; 67(4):1401-7. PubMed ID: 812503
    [No Abstract]   [Full Text] [Related]  

  • 55. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Fenofibrate: chemical development and differences with clofibrate (author's transl)].
    Boucherle A
    Nouv Presse Med; 1980 Dec; 9(49):3721-3. PubMed ID: 7208336
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins.
    Sallustio BC; Knights KM; Roberts BJ; Zacest R
    Biochem Pharmacol; 1991 Sep; 42(7):1421-5. PubMed ID: 1930265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure.
    Desager JP; Costermans J; Verberckmoes R; Harvengt C
    Nephron; 1982; 31(1):51-4. PubMed ID: 7110477
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
    Rouffy J; Chanu B; Bakir R; Djian F; Goy-Loeper J
    Atherosclerosis; 1985 Mar; 54(3):273-81. PubMed ID: 3994783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypolipidemic drug clofibrate promotes hepatic tumor.
    Nagini S; Nagarajan B
    Biochem Int; 1988 Oct; 17(4):605-10. PubMed ID: 3240312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.